Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(20%)
Results Posted
200%(2 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
3
60%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(1)
Terminated(3)

Detailed Status

Terminated2
Completed1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

completed120%
withdrawn120%
terminated240%
active_not_recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
terminatedphase_2

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

NCT03894215
active_not_recruitingphase_1

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

NCT05205330
completedphase_1

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

NCT03104699
terminatedphase_2

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

NCT04430036
withdrawnphase_2

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

NCT04607200

Clinical Trials (5)

Showing 5 of 5 trials
NCT03894215Phase 2

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Terminated
NCT05205330Phase 1

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Active Not Recruiting
NCT03104699Phase 1

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Completed
NCT04430036Phase 2

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Terminated
NCT04607200Phase 2

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5